FDA Clearance Tracker · P220012
Aurora EV-ICD System
Last checked: Nov 19, 2026Latest source record: Oct 20, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Oct 20, 2023
Approved
Time to decision
434 days
Received Aug 12, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P220012
- Device name
- Aurora EV-ICD System
- Applicant
- Medtronic, Inc.
- Applicant location
- Mounds View, MN
- Received
- Aug 12, 2022
- Decided
- Oct 20, 2023
- Decision
- Approved
- Supplements
- 75 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
the automated treatment of patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias through the delivery of antitachycardia pacing, cardioversion, and defibrillation therapies. Medical conditions that may indicate a patient for an EV-ICD for primary or secondary prevention of sudden cardiac death due to life-threatening ventricular tachyarrhythmias include: Previous ventricular tachyarrhythmias Coronary disease with left ventricular dysfunction Cardiomyopathy Inherited primary arrhythmia syndromes Congenital heart diseaseNote: For patient-specific recommendations regarding indications for primary and secondary prevention of sudden cardiac death, refer to current clinical guidelines from the European Society of Cardiology (ESC), American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS).The Epsila EV MRI SureScan Model EV2401 extravascular lead is indicated for use in the anterior mediastinum for pacing therapies, cardioversion, and defibrillation when an extravascular implantable cardioverter defibrillator is indicated to treat patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. The Epsila EV EAZ101 Sternal Tunneling Tool is indicated for use in the implant of a compatible anterior mediastinum defibrillation lead.The Epsila EV EAZ201 Transverse Tunneling Tool is indicated for use in the implant of a compatible anterior mediastinum defibrillation lead.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LWS. The earliest in FDA's data is P830060, decided Oct 4, 1985.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
K262913 · Decided Sep 17, 2026 · 29 days after receipt
Device type: Stents, Drains And Dilators For The Biliary Ducts (FGE) · GI, Urology & Nephrology
K262735 · Decided Aug 28, 2026 · 28 days after receipt
Device type: Recorder, Event, Implantable Cardiac, (With Arrhythmia Detection) (MXD) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.